Dare Bioscience (NASDAQ:DARE) Stock Crosses Below 50 Day Moving Average of $0.79

Dare Bioscience Inc (NASDAQ:DARE)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.79 and traded as low as $0.78. Dare Bioscience shares last traded at $0.84, with a volume of 23,505 shares trading hands.

Several brokerages have recently issued reports on DARE. ValuEngine raised Dare Bioscience from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Dare Bioscience in a research report on Thursday, May 16th. Finally, Aegis started coverage on Dare Bioscience in a research report on Thursday. They set a “buy” rating on the stock.

The firm has a market capitalization of $13.78 million, a price-to-earnings ratio of -0.76 and a beta of 1.96. The business has a 50-day moving average of $0.79 and a two-hundred day moving average of $0.95.

Dare Bioscience (NASDAQ:DARE) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). Sell-side analysts predict that Dare Bioscience Inc will post -0.88 EPS for the current fiscal year.

A hedge fund recently raised its stake in Dare Bioscience stock. Susquehanna International Group LLP increased its position in shares of Dare Bioscience Inc (NASDAQ:DARE) by 293.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,770 shares of the biotechnology company’s stock after buying an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned 0.26% of Dare Bioscience worth $36,000 at the end of the most recent quarter. 5.28% of the stock is owned by institutional investors.

About Dare Bioscience (NASDAQ:DARE)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Recommended Story: How to invest in a bear market

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.